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Table 1. Baseline characteristics, perceived barriers and acceptance of the HPV vaccine; comparing respondents and non-respondents of the
follow-up study.
TOTAL BASELINE
(n = 287)
FOLLOW-UP RESPONDENTS
(n = 256)
NON-RESPONDENTS
(n = 31)
BASELINE CHARACTERISTICS
Median (IQR) Median (IQR) Median (IQR) p-
value
Participant age at baseline 35 (32–40) 35 (32–40) 35 (39–40) 0.43
Range (years) 21–59 21–59 23–56
Age of daughter at baseline 12 (11–14) 12 (11–14) 12 (11–13) 0.68
Range (years) 8–18 8–18 8–17
Years of education of participant 8 (7–12) 8 (7–12) 8 (6–11) 0.35
Range (years)* 0–13+ 0–13+ 0–13+
Housing characteristics** 5 (4–5) 5 (4–5) 5 (4–6) 0.04
Range 1–7 2–7 3–7
n (%) n (%) n (%) p-
value
Marital status of participant 0.85
With partner 217 (75.6) 194 (75.8) 23 (74.2)
Without partner 70 (24.4) 62 (24.2) 8 (25.8)
Religious afﬁliation of participant 0.48
Protestant 226 (79.3) 204 (80.3) 22 (71.0)
Catholic 46 (16.1) 39 (15.3) 7 (22.6)
Muslim 13 (4.6) 11 (4.3) 2 (6.4)
Origin of participant*** 0.98
urban 171 (60.2) 153 (60.2) 18 (60.0)
rural—outside Kenya 113 (39.8) 101 (39.8) 12 (40.0)
Ever heard of cervical cancer? 0.37
No—don’t know 117 (40.9) 102 (40.0) 15 (48.4)
Yes 169 (59.1) 153 (60.0) 16 (51.6)
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need more information? 0.40
(strongly) disagree 98 (34.6) 84 (33.3) 14 (45.2)
neutral 17 (6.0) 15 (5.9) 2 (6.4)
(strongly) agree 168 (59.4) 153 (60.7) 15 (48.4)
Doubt the vaccine works? 0.36
(strongly) disagree 197 (70.1) 174 (69.6) 23 (74.2)
neutral 24 (8.5) 20 (8.0) 4 (12.9)
(strongly) agree 60 (21.3) 56 (22.4) 4 (12.9)
Fear of side effects? 0.26
(strongly) disagree 149 (52.5) 129 (51.0) 20 (64.5)
neutral 27 (9.5) 26 (10.3 1 (3.2)
(strongly) agree 108 (38.0) 98 (38.7) 10 (32.3)
Fear of interference with fertility? 0.43
(strongly) disagree 171 (60.4) 149 (59.1) 22 (71.0)
neutral 45 (15.9) 41 (16.3) 4 (12.9)
(strongly) agree 67 (23.7) 62 (24.6) 5 (16.1)
Afraid of unsafe administration? 0.07
(strongly) disagree 203 (71.7) 177 (70.2) 26 (83.9)
(Continued)
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Table 1. (Continued)
TOTAL BASELINE
(n = 287)
FOLLOW-UP RESPONDENTS
(n = 256)
NON-RESPONDENTS
(n = 31)
neutral 17 (6.0) 14 (5.6) (9.7)
(strongly) agree 63 (22.3) 61 (24.2) 2 (6.4)
It might encourage unsafe sex 0.94
(strongly) disagree 238 (84.7) 212 (84.8) 26 (83.9)
neutral 23 (8.2) 20 (8.0) 3 (9.7)
(strongly) agree 20 (7.1) 18 (7.2) 2 (6.4)
Daughter is too young for vaccine against an
STI?
0.91
(strongly) disagree 250 (88.3) 222 (88.1) 28 (90.3)
neutral 9 (3.2) 8 (3.2) 1 (3.2)
(strongly) agree 24 (8.5) 22 (8.7) 2 (6.4)
Partner won’t approve? 0.70
(strongly) disagree **** 221 (78.4) 196 (78.1) 25 (80.6)
neutral 30 (10.6) 28 (11.2) 2 (6.4)
(strongly) agree 31 (11.0) 27 (10.8) 4 (12.9)
Vaccination takes a lot of time 0.75
(strongly) disagree 275 (96.8) 245 (96.8) 30 (96.8)
neutral 6 (2.1) 5 (2.0) 1 (3.2)
(strongly) agree 3 (1.1) 3 (1.2) 0 (0.00)
Inconvenience of 3 doses needed 0.08
(strongly) disagree 265 (96.0) 236 (96.3) 29 (93.5)
neutral 6 (2.2) 6 (2.4) 0 (0.0)
(strongly) agree 5 (1.8) 3 (1.2) 2 (6.4)
BASELINE ACCEPTANCE
Would you vaccinate your daughter against
cervical cancer?
0.69
very unlikely 6 (2.1) 6 (2.3) 0 (0.0)
unlikely 3 (1.0) 3 (1.2) 0 (0.0)
neutral 25 (8.7) 21 (8.2) 4 (12.9)
likely 80 (27.9) 73 (28.5) 7 (22.6)
very likely 173 (60.3) 153 (59.8) 20 (64.5)
IQR = interquartile range
*13+: those who studied in higher education i.e. college (middle level) and/or university
**housing: continuous variable constructed by scoring aspects of the living place: material of the roof, walls and ﬂoors, and toilet and water facilities
*** women were asked where they had lived for most of the time up to 12 years of age
**** includes participants without a relationship
doi:10.1371/journal.pone.0117761.t001
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Table 2. Bivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.
VARIABLE BASELINE ACCEPTANCE UPTAKE
n Acceptance
(%)
AOR [95% CI] n Uptake (%) AOR [95% CI]
BASELINE CHARACTERISTICS
Participant age at baseline 286 1.05* [1.01–1.08] 254 1.01 [0.97–1.04]
Age of daughter at baseline 285 1.14 [0.85–1.54] 253 1.03 [0.86–1.23]
Years of education of participant 279 0.10 [0.88–1.23] 247 1.05 [0.99–1.11]
Housing 287 0.81 [0.61–1.08] 255 1.12 [0.74–1.70]
Marital status of participant 287 255
With partner 188/217 (86.6) 57/193 (29.5)
Without partner 65/70 (92.9) 0.53 [0.15–1.84] 22/62 (35.5) 0.75 [0.43–1.32]
Religion of participant 285 253
Protestant 202/226 (89.4) 58/203 (28.6)
Catholic 41/46 (89.1) 1.07 [0.23–4.88] 17/39 (43.6) 1.92* [1.19–3.09]
Muslim 8/13 (61.5) 0.20 [0.04–1.09] 4/11 (36.4) 1.42 [0.48–4.18]
Origin of participant 284 253
Urban 155/171 (90.6) 56/153 (36.6)
Rural—outside Kenya 96/113 (85.0) 0.61 [0.19–1.94] 22/100 (22.0) 0.48 [0.21–1.10]
Ever heard of cervical cancer? 286 254
No—don’t know 107/117 (91.4) 24/102 (23.5)
Yes 145/169 (85.8) 0.55 [0.22–1.37] 55/152 (36.2) 1.93* [1.16–3.19]
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need for more information? 283 1.00 [0.84–1.20] 251 1.02 [0.89–1.17]
Doubt the vaccine works? 281 0.75* [0.59–0.97] 249 0.98 [0.76–1.26]
Fear of side effect? 284 0.69* [0.52–0.91] 252 1.00 [1.76–1.31]
Fear of interference with fertility? 283 0.71* [0.53–0.96] 251 0.94 [0.71–1.25]
Afraid of unsafe administration (i.e. using unclean
needles)
283 0.76** [0.64–0.91] 251 1.04 [0.78–1.40]
It might encourage unsafe sex 282 0.80 [0.53–1.20] 250 0.81 [0.52–1.26]
Daughter is too young for vaccine against an STI? 283 0.54** [0.38–0.76] 251 0.94 [0.61–1.43]
Partner won’t approve?° 282 0.44*** [0.31–0.61] 250 0.87 [0.68–1.09]
Vaccination takes a lot of time 284 0.51 [0.24–1.12] 252 0.86 [0.60–1.21]
Inconvenience: 3 doses needed 276 0.67 [0.36–1.24] 244 0.94 [0.57–1.55]
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (Baseline) 255
neutral—(very) unlikely 5/30 (16.7) -
(very) likely 74/225 (32.9) 2.57* [1.11–5.94]
Were you well-informed about the cervical cancer
vaccination program? (at follow-up)
235
No 10/88 (11.4) -
Yes 68/147 (46.3) 6.37** [2.21–18.36]
AOR: adjusted odds ratio—CI: conﬁdence interval
° participants without a relationship are included in category ‘strongly disagree’
* p<0.05
** p<0.01
*** p<0.001
doi:10.1371/journal.pone.0117761.t002
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Table 3. Multivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.
ACCEPTANCE—AOR [95% CI] UPTAKE—AOR [95% CI]
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 4
n = 270 n = 278 n = 280 n = 239 n = 246 n = 247 n = 227
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (at baseline) 3.36
(very) likely (ref: neutr.–(very) unlikely) [0.80–14.1]
Were you well-informed about the vaccination program? (at follow-up) 6.37**
Yes (ref: No) [2.24–18.1]
BASELINE CHARACTERISTICS
Age of participant at baseline 1.06* 1.003
[1.00–1.12] nw [0.96–1.04] nw
Age of daughter at baseline 1.05 1.088
[0.77–1.44] nw [0.86–1.37] nw
Years of education of participant 0.98 1.051
[0.89–1.08] nw [0.97–1.14] nw
Housing 0.90 nw 0.972
[0.64–1.26] [0.60–1.56] nw
Marital status of participant
Without partner (ref: with partner) 0.56 0.689
[0.15–2.00] nw [0.37–1.29] nw
Religion of participant. (ref: protestant.)
Catholic 1.35 1.416
[0.28–6.42] [0.57–3.50]
Muslim 0.078** 1.171
[0.02–0.38] nw [0.42–3.26] nw
Origin of participant
rural—outside Kenya (ref: urban) 0.49 0.546 0.48* 0.53*
[0.15–1.62] nw [0.21–1.42] [0.23–0.99] [0.29–0.97]
Ever heard of cervical cancer? (at baseline) 0.43 0.46 1.610* 1.84* 2.07*
Yes (ref: No–don’t know) [0.17–1.11] [0.17–1.30] [1.09–2.38] [1.04–3.26] [1.18–3.63]
BARRIERS AT BASELINE
Need for more information 1.21 0.99
[0.86–1.71] nw [0.83–1.18] nw
Barriers inherent to vaccination° 0.86 1.06
[0.56–1.33] nw [0.68–1.63] nw
It might encourage unsafe sex 0.94 0.82
[0.57–1.53] nw [0.49–1.37] nw
Daughter is too young for vaccine against an STI? 0.72 0.67* 0.99
[0.48–1.10] [0.45–0.99] [0.57–1.69] nw
Partner won’t approve? 0.50** 0.47*** 0.89 0.83 0.99
[0.33–0.74] [0.32–0.71] [0.68–1.16] [0.67–1.03] [0.74–1.32]
Barriers related to time constraints°° 0.68 1.00
[0.27–1.69] nw [0.57–1.74] nw
Cons 9.86 103.60** 138.38*** 0.20 0.68 1.07 0.06*
(Continued)
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Table 3. (Continued)
ACCEPTANCE—AOR [95% CI] UPTAKE—AOR [95% CI]
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 4
n = 270 n = 278 n = 280 n = 239 n = 246 n = 247 n = 227
F-statistic (p) 410.3 (0.04) 14.15 (0.01) 13.93 (0.00) 2.661 (0.44) 0.304 (0.91) 5.916 (0.02) 4.443 (0.06)
Model 1: including baseline characteristics; model 2: including barriers perceived at baseline; model 3: including baseline characteristics and barriers
obtained by stepwise backward regression—model 4: model 3 + acceptance and being well-informed about the HPV vaccination program
AOR: adjusted odds ratio—CI: conﬁdence interval
°average of: doubt the vaccine works, fear of side effects and interference with fertility, and afraid of unsafe administration; alpha = 0.90
°° average of: vaccination takes a lot of time and 3 doses are inconvenient; alpha = 0.79
nw: not withheld in backward stepwise regression
* p<0.05
** p<0.01
*** p<0.00
doi:10.1371/journal.pone.0117761.t003
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